Helpdesk

Sales contact

Home > Resources > eCOA setup: How to ensure a successful launch by navigating complexities

eCOA setup: How to ensure a successful launch by navigating complexities

Last updated : June 24, 2024

Discover the presentation on eCOA setup held by Estelle Haenel, Medical Director @Kayentis, during Clinical Trials Europe and Outsourcing in Clinical Trials Europe!

https://youtu.be/-eDdjoy_MCkCONTENTS

Prepare Specifications

: how to mitigate risk and anticipate complexities

User Acceptance Testing

: who is responsible for performing the UAT and why?

eCOA back up strategy

: how to make sure it will be adapted to every situation (even the unexpected ones?)

keep the patient and the site at the heart of the decisions

without jeopardizing data integrity?

Estelle Haenel, Medical Director @Kayentis

Learn more:

eCOA set-up #whitepaper Plan a successful web back-up strategy for your clinical trials #infographic eCOA challenges of long term studies #whitepaper

Subscribe to our newsletter

Turning experience into evidence: PROs in IBD clinical research

BYOD on the rise

Strategies to promote BYOD adoption by clinical study sites

How Kayentis reduces the CO2 emissions of your eCOA projects...

Empowering patients through data: a collaborative vision of clinical data...

If Patients Want A Better Quality Of Life, Why Isn’t...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

5th Annual Clinical Trial Innovation Summit

JUNE 26, 2025 • Basel, CH

Clinical Trial Innovation Summit 2025 | June 26, 2025

The reckless value of Patient Reported Outcomes (PROs) for Emerging Biopharma Companies – Webinar

July 9 • 11-12AM EDT / 4-5PM GMT / 5-6PM CET

In today’s competitive landscape, biotech and emerging biopharma companies (EBPs) must demonstrate the value of their innovations early and convincingly....